Evidence map›Paper›PMID 35493305›Full record

ArticleDisease markers2022

Comprehensive Characterization of the Function of Metabolic Genes and Establishment of a Prediction Model in Breast Cancer.

Ruijing Yu, Mengle Peng, Shuai Zhao, Zhongquan Wang, Yajie Ma, Xinyu Zhang, Xuefeng Lv, Shukai Wang, Shaotan Ju, Rongling Zhao and 2 more

Abstract read
In one paragraph

Article in Disease markers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ruijing YuDepartment of Clinical Laboratory, Henan Provincial Third People's Hospital, Zhengzhou, 450006 Henan, China.
Mengle PengDepartment of Clinical Laboratory, Henan Provincial Third People's Hospital, Zhengzhou, 450006 Henan, China.
Shuai ZhaoDepartment of Clinical Laboratory, Henan Provincial Third People's Hospital, Zhengzhou, 450006 Henan, China.
Zhongquan WangDepartment of Clinical Laboratory, Henan Provincial Third People's Hospital, Zhengzhou, 450006 Henan, China.
Yajie MaDepartment of Neurology, Henan Provincial Third People's Hospital, Zhengzhou, 450006 Henan, China.
Xinyu ZhangDepartment of Medical Affair, Henan Provincial Third People's Hospital, Zhengzhou, 450006 Henan, China.
Xuefeng LvDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Shukai WangDepartment of Clinical Laboratory, Henan Provincial Third People's Hospital, Zhengzhou, 450006 Henan, China.
Shaotan JuDepartment of Clinical Laboratory, Henan Provincial Third People's Hospital, Zhengzhou, 450006 Henan, China.
Rongling ZhaoDepartment of Clinical Laboratory, Henan Provincial Third People's Hospital, Zhengzhou, 450006 Henan, China.
Qing ZhouRehabilitation Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.ORCID https://orcid.org/0000-0002-8227-4616
Wenping LianDepartment of Clinical Laboratory, Henan Provincial Third People's Hospital, Zhengzhou, 450006 Henan, China.ORCID https://orcid.org/0000-0001-7864-9537

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Breast cancer (BC) is a highly heterogeneous disease with high morbidity and mortality. Its subtypes may have distinctly different biological behaviors, clinical outcomes, and therapeutic responses. The metabolic status of BC tissue is closely related to its progress. Therefore, we comprehensively characterized the function of metabolic genes in BC and identified new biomarkers to predict BC patients' prognoses. Methods: Metabolic genes were identified by intersecting genes obtained from two published pieces of literature. The function of metabolic genes in BC was determined by extracting differentially expressed genes (DEGs), performing functional enrichment analyses, analyzing the infiltrating proportion of immune cells, and conducting metabolic subgroup analyses. A risk score model was constructed to assess the prognoses of BC patients by performing the univariate Cox regression, LASSO algorithm, multivariate Cox regression, Kaplan-Meier survival analyses, and ROC curve analyses in the training set. The prognostic model was then validated on the testing dataset, external dataset, the whole TCGA-BC database, and our clinical specimens. Finally, a nomogram was constructed for clinical prognostic prediction based on the risk score model and other clinicopathological parameters. Results: 955 metabolic genes were obtained. Among these, 157 metabolic DEGs were identified between BC and normal tissues for subsequent GO and KEGG pathway enrichment analyses. 5 metabolic genes were negatively correlated with CD8 Conclusion: In this study, we elucidated tumor heterogeneity from metabolite profiling of BC. The roles of metabolic genes in the occurrence of BC were comprehensively characterized, clarifying the relationship between the tumor microenvironment (TME) and metabolic genes. Meanwhile, a concise prediction model was also constructed based on metabolic genes, providing a convenient and precise method for the individualized diagnosis and treatment of BC patients.

Indexed as

Breast NeoplasmsCD8-Positive T-LymphocytesFemaleHumansNeoplasm StagingNomogramsPrognosisTumor Microenvironment

Identifiers

PMID35493305
PMCPMC9042645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.